Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
ACHV
ACHIEVE LIFE SCIENCES, INC.
NASDAQ
$7.24
▲ UP 2.99% (0.21)

KEY STATISTICS

Market Cap$743.25 M
52w High$8.64
52w Low$2.62
Dividend Yield—
Frequency—
P/E-4.67
Volume1.04M
Shares Out.102.66M

COMPANY

LEADERSHIP

Andrew D. Goldberg
CHIEF EXECUTIVE
Andrew D. Goldberg

COMPENSATION 2026

Salary$615,000
Stock Awards$522,900
Incentive Plan Pay$230,625
All Other Comp.$0
Total$1,368,525

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 12, 1995
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
28

PRICE TARGET

Target High$18.00
Target Low$12.00
Target Median$13.00
Target Consensus$14.80

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$10.65M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2020-07-31Reverse1:20
2018-05-24Reverse1:10
2017-08-03Reverse1:11
2008-08-21Reverse1:18

ETFS HOLDING THIS STOCK

ETFS HOLDING
69
LISTED HERE
10
RANKED BY POSITION SIZE
VTS.AX
0.00%
3.1M
XBI
0.14%
2.1M
XSU.TO
0.02%
2.0M
SURI
8.89%
932.1K
FESM
0.03%
311.3K
DWAS
0.34%
197.0K
LABU
0.11%
101.6K
XRS2.F
0.02%
67.7K
BBC
0.95%
57.5K
GSSC
0.03%
39.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
19.14%
HOLDERS
110
TOP 8 OF 110 · RANKED BY POSITION SIZE
Franklin Resources Inc
4.4M sh
$12.85M
Propel Bio Management, LLC
3.8M sh
$18.82M
Alyeska Investment Group, L.P.
3.5M sh
$7.92M
Vanguard Group Inc
2.5M sh
$12.3M
Blackrock Inc.
2.0M sh
$9.2M
Millennium Management LLC
1.4M sh
$6.75M
Simplify Asset Management Inc.
1.2M sh
$3.73M
Marshall Wace, Llp
1.0M sh
$5.07M

PRICE

$7.24 ▲ UP 2.99% (+$0.21)
OVERLAYS
$7.05$7.20$7.359:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM7.24

About Achieve Life Sciences, Inc.

https://www.achievelifesciences.com ↗

Achieve Life Sciences, a Vancouver-based clinical-stage pharma company, develops cytisinicline for smoking cessation and nicotine addiction in North America and the UK, with licensing agreements with Sopharma AD and the University of Bristol.

INDUSTRY

Biotechnology

A PRODUCT ACHIEVE LIFE SCIENCES, INC. IS KNOWN FOR

Cytisinicline
Cytisinicline

Cytisinicline, a plant-based alkaloid developed by Achieve Life Sciences, is a leading investigational treatment for smoking cessation and nicotine dependence, with an NDA under review by the FDA.

COMPETITORS

COMPETITOR
AXSM COMPARE
GSK COMPARE
PFE COMPARE
PRGO COMPARE
VTRS COMPARE

Achieve Life Sciences in 2025

SENTIMENT: + POSITIVE
Dr. Martin Makary
REGULATORY · OCTOBER 2025

Achieve Life Sciences Awarded Inaugural FDA Commissioner's National Priority Voucher for Vaping Cessation Drug, Sparking Significant Stock Surge

In October 2025, Achieve Life Sciences received one of the first-ever Commissioner's National Priority Vouchers from the U.S. Food and Drug Administration (FDA) for its drug candidate, cytisinicline, as a potential treatment for e-cigarette and vaping cessation. This recognition, part of a new FDA program to incentivize treatments for national health priorities, provided for an expedited review process and significantly boosted investor confidence in the drug's potential, highlighting a major unmet medical need.

PARTNERSHIP · JUNE 2025 · IN PROGRESS

Achieve Life Sciences Forges Strategic Partnership with Omnicom to Engineer an 'Innovative, Data-Driven' Commercial Launch for Cytisinicline

Achieve Life Sciences made a pivotal decision to partner with global marketing and communications giant Omnicom to spearhead the commercial launch of its sole product candidate, cytisinicline. This strategic move outsources the development and execution of a fully integrated launch strategy, leveraging a unified team of seven specialized Omnicom agencies to reduce commercial buildout costs and accelerate market entry.

Latest News

GLOBENEWSWIRE · OCT 7, 2026

Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications

SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Kaitlyn (Kait) Tuson as Senior Vice President, Marketing and Communications. Tuson joins Achieve's executive team and will lead its marketing, brand strategy, and corporate communications as the Company prepares for the potential commercialization of cytisinicline.

READ ARTICLE
EARLIER COVERAGE
GLOBENEWSWIRE · OCT 6, 2026

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate of 46,500 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 44,500 shares of its common stock for four new employees. Achieve also announced that the board of directors approved an inducement award grant to Benjamin Halladay, the Company's newly appointed Chief Financial Officer, consisting of an option to purchase up to 200,000 shares of common stock and 200,000 RSUs.

READ ARTICLE
DEFENSE WORLD · OCT 2, 2026

Achieve Life Sciences (NASDAQ:ACHV) Shares Gap Up – Here’s What Happened

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report)'s stock price gapped up before the market opened on Wednesday. The stock had previously closed at $7.69, but opened at $8.08. Achieve Life Sciences shares last traded at $8.0310, with a volume of 186,199 shares traded. Analysts Set New Price Targets Several analysts have recently weighed

READ ARTICLE
GLOBENEWSWIRE · OCT 1, 2026

Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer

Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline

READ ARTICLE

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
ALLO$1.47COMPARE
CAPR$7.71COMPARE
AVIR$5.06COMPARE
ARCT$13.23COMPARE
SGMT$8.78COMPARE
VNDA$4.50COMPARE
TRDA$5.38COMPARE
VYGR$2.44COMPARE

INSIDER TRADES

★
Halladay Benjamin
— · —
2026-10-05
★
OFFICER: CHIEF FINANCIAL OFFICER
Halladay Benjamin
Purchase · 200.0K shares
2026-10-05
★
OFFICER: CHIEF FINANCIAL OFFICER
Halladay Benjamin
Purchase · 200.0K shares
2026-10-05
★
DIRECTOR
Stewart Richard Alistair
Sale · 20.6K shares
2026-08-19